ABB
The Board of Directors of ABB and its CEO Ulrich Spiesshofer (55) have mutually agreed for him to step down from his role, which he has held since 2013. The Chairman of the Board, Peter Voser (61), will become interim CEO in addition to his current role with immediate effect. An official search to find a new CEO has been initiated.
Peter Voser: “On behalf of the Board and the employees of ABB, I would like to personally thank Ulrich for his dedication and commitment to ABB’s customers and employees, not only as CEO, but also in other executive roles at ABB since 2005. Under his leadership, ABB has been transformed into a global technology leader focused in digital industries. He strategically repositioned the company and built up growth momentum across all businesses. We wish him all the best for his future endeavors.”
Voser added: “We will continue to focus on implementing ABB’s strategy and delivering value to all our stakeholders. To achieve our key financial targets, we will proceed with the divestment of ABB’s Power Grids business as planned, simplify the organizational structure of the group and deliver cost savings. Finally, our four new leading businesses will be fully dedicated to meet our customer needs for digitalization, electrification, automation and robotics.”
Ulrich Spiesshofer: “After 14 years of 'all in' dedication and commitment to all our employees and customers, I hand over to Peter a trimmed ABB ship that is on a clear course and gaining speed. I would like to warmly thank our colleagues around the world, customers and partners as well as the Board of Directors for the opportunity to serve this fine company for nearly one and a half decades in different roles in the Executive Committee and as CEO. I will now take some time out before deciding on the next chapter of my professional life. From the bottom of my heart, I wish ABB’s global team all the very best for its future.”
Peter Voser, a Swiss citizen, has been Chairman of ABB since April 2015. Prior to this, he was CEO of Royal Dutch Shell from 2009-2013, and CFO between 2004-2009. Between 2002 and October 2004, he was CFO of ABB and a key leader behind the successful turnaround of the company. Voser also brings a wealth of experience in board positions in leading companies such as a Roche, IBM, Catalyst, Temasek Holdings and PSA International in Singapore.
ABB will hold its Annual General Meeting on May 2, 2019, in Zurich, as planned.
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market-leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com
This information is information that ABB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 6.45 a.m. CEST on April 17, 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190416006089/en/
Contact:
ABB Ltd Affolternstrasse 44 8050 Zurich Switzerland Media Relations Phone: +41 43 317 71 11 Email: media.relations@ch.abb.com or Investor Relations Jessica Mitchell Phone: +41 43 317 71 11 Email: investor.relations@ch.abb.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 14:00:00 CEST | Press release
Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison
Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 13:45:00 CEST | Press release
Norwegian technology provider Cyviz has successfully developed a fully mobile and ballistic-proof command center - designed, configured, and made operational in just 24 hours. The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You do
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom